肝细胞癌病因的预后评分与生存率：综述
Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review.
作者信息
Calderon-Martinez Evelyn, Landazuri-Navas Samanta, Vilchez Esmeralda, Cantu-Hernandez Raul, Mosquera-Moscoso Johanna, Encalada Sebastian, Al Lami Zahraa, Zevallos-Delgado Christian, Cinicola John
机构信息
Department of Internal Medicine, UPMC Harrisburg, Harrisburg, PA, USA.
Department of Internal Medicine, University of the Americas, Quito, Ecuador.
出版信息
J Clin Med Res. 2023 Apr;15(4):200-207. doi: 10.14740/jocmr4902. Epub 2023 Apr 28.
Abstract
Hepatocellular carcinoma (HCC) is a common cancer and ranks sixth among all malignancies worldwide. Risk factors for HCC can be classified as infectious or behavioral. Viral hepatitis and alcohol abuse are currently the most common risk factors for HCC; however, nonalcoholic liver disease is expected to become the most common cause of HCC in upcoming years. HCC survival rates vary according to the causative risk factors. As in any malignancy, staging is crucial in making therapeutic decisions. The selection of a specific score should be individualized according to patient characteristics. In this review, we summarize the current data on epidemiology, risk factors, prognostic scores, and survival in HCC.
摘要
肝细胞癌（HCC）是一种常见癌症，在全球所有恶性肿瘤中排名第六。HCC的危险因素可分为感染性或行为性。病毒性肝炎和酗酒是目前HCC最常见的危险因素；然而，预计非酒精性肝病在未来几年将成为HCC最常见的病因。HCC的生存率因致病危险因素而异。与任何恶性肿瘤一样，分期对于做出治疗决策至关重要。应根据患者特征个体化选择特定的评分系统。在本综述中，我们总结了目前关于HCC的流行病学、危险因素、预后评分和生存率的数据。
相似文献
1
Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review.
J Clin Med Res. 2023 Apr;15(4):200-207. doi: 10.14740/jocmr4902. Epub 2023 Apr 28.
2
Increased prevalence but decreased survival of nonviral hepatocellular carcinoma compared to viral hepatocellular carcinoma in recent ten years.
Sci Rep. 2024 Apr 20;14(1):9068. doi: 10.1038/s41598-024-59668-2.
3
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs.
JHEP Rep. 2023 May 5;5(8):100784. doi: 10.1016/j.jhepr.2023.100784. eCollection 2023 Aug.
4
Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy.
World J Gastrointest Oncol. 2024 Mar 15;16(3):761-772. doi: 10.4251/wjgo.v16.i3.761.
5
Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany.
Int J Clin Exp Med. 2010 Jun 10;3(2):169-79.
6
Current epidemiology in hepatocellular carcinoma.
Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1295-1307. doi: 10.1080/17474124.2021.1991792. Epub 2021 Oct 22.
7
Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease.
Liver Cancer. 2012 Nov;1(3-4):257-66. doi: 10.1159/000343840.
8
Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
Cancer. 2018 Jun 15;124(12):2588-2598. doi: 10.1002/cncr.31373. Epub 2018 Apr 6.
9
Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis.
Abdom Radiol (NY). 2018 Jan;43(1):13-25. doi: 10.1007/s00261-017-1209-1.
10
Epidemiology, mutational landscape and staging of hepatocellular carcinoma.
Chin Clin Oncol. 2021 Feb;10(1):2. doi: 10.21037/cco-20-162.
引用本文的文献
1
Evolutionary dynamics of recurrent hepatocellular carcinoma under divergent immune selection pressures.
Front Oncol. 2025 Aug 4;15:1537087. doi: 10.3389/fonc.2025.1537087. eCollection 2025.
2
Breaking Barriers with Sound: The Implementation of Histotripsy in Cancer.
Cancers (Basel). 2025 Aug 1;17(15):2548. doi: 10.3390/cancers17152548.
3
Health-related quality of life in Thai patients with hepatocellular carcinoma and its influencing factors: A cross-sectional study.
Belitung Nurs J. 2025 Aug 3;11(4):370-383. doi: 10.33546/bnj.3853. eCollection 2025.
4
Incidence of hepatocellular carcinoma in beta thalassemia: a systematic review and meta-analysis.
Hematol Transfus Cell Ther. 2025 Jul-Sep;47(3):103934. doi: 10.1016/j.htct.2025.103934. Epub 2025 Jul 31.
5
Determinants of Survival and Prognostic Factors in Patients Undergoing Liver Resection for Primary Hepatic Carcinoma-A Follow-Up Study.
Clin Pract. 2025 Jun 26;15(7):121. doi: 10.3390/clinpract15070121.
6
Hepatocellular Carcinoma in South Indian Population: Clinical Profile and AFP Correlation with Radiological Tumor Size.
J Pharm Bioallied Sci. 2025 Jun;17(Suppl 2):S1940-S1945. doi: 10.4103/jpbs.jpbs_1864_24. Epub 2025 Jun 18.
7
Imiquimod-Loaded Phospholipid-Free Small Unilamellar Vesicles Activate the Tumor Immune Microenvironment to Treat Liver Cancer and Liver Metastases.
Adv Healthc Mater. 2025 Aug;14(22):e2501691. doi: 10.1002/adhm.202501691. Epub 2025 Jun 17.
8
Prognostic Significance of lncRNA ATB and SNHG16 Expression Levels in Patients with Hepatocellular Carcinoma.
Iran J Pathol. 2025 Spring;20(2):152-158. doi: 10.30699/ijp.2025.2044199.3368. Epub 2025 Oct 30.
9
Functional Role of NOXA in Hypoxia-Mediated PD-L1 Inhibitor Response in Hepatocellular Carcinoma.
Int J Mol Sci. 2025 May 16;26(10):4766. doi: 10.3390/ijms26104766.
10
Rare Coexisting Hepatocellular and Gallbladder Carcinomas: A Case Report.
Am J Case Rep. 2025 May 7;26:e946739. doi: 10.12659/AJCR.946739.
本文引用的文献
1
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis.
Cancers (Basel). 2023 Jan 6;15(2):381. doi: 10.3390/cancers15020381.
2
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
J Hepatol. 2022 Oct;77(4):1136-1160. doi: 10.1016/j.jhep.2022.06.012. Epub 2022 Jun 22.
3
Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255].
Ann Oncol. 2022 Jun;33(6):666. doi: 10.1016/j.annonc.2022.03.009. Epub 2022 Mar 30.
4
IGF-1 contributes to liver cancer development in diabetes patients by promoting autophagy.
Ann Hepatol. 2022 Jul-Aug;27(4):100697. doi: 10.1016/j.aohep.2022.100697. Epub 2022 Mar 14.
5
Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019.
J Viral Hepat. 2022 May;29(5):352-365. doi: 10.1111/jvh.13663. Epub 2022 Mar 15.
6
Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach.
Cancers (Basel). 2021 Nov 21;13(22):5844. doi: 10.3390/cancers13225844.
7
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
8
Current epidemiology in hepatocellular carcinoma.
Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1295-1307. doi: 10.1080/17474124.2021.1991792. Epub 2021 Oct 22.
9
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification.
Adv Cancer Res. 2021;149:1-61. doi: 10.1016/bs.acr.2020.10.001. Epub 2020 Nov 28.
10
Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV: more aggressive tumor behavior?
Eur J Gastroenterol Hepatol. 2021 Apr 1;33(4):583-588. doi: 10.1097/MEG.0000000000002057.
Zotero 插件